TLSA Tiziana Life Sciences Ltd

$TLSA very few, if any longs will be selling tlsa before October 2026 ph 2 results which will start creating momentum. good results that prove mechanism of action could lead to stock rocketing to $5 or higher.

$TLSA Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease

$TLSA looks to be forming an inverse head and shoulders on daily with a re-test of broad inverse head and shoulders on monthly. bullish tlsa.

$TLSA not financial advice but some observations we were trading at $2.50 last July. What changed in a little over one year other than better fundamentals from strong execution, several positive clinical updates, several substantial insider buying, international partnership and getting much closer to our data update ? Oh yeah a little dilution from ATM that is some necessary balance sheet strengthening and it’s nothing in the big picture relative to our TAM. Am I missing something?

$TLSA “In addition to treating patients with Alzheimer’s, researchers across Mass General Brigham are testing foralumab in patients with multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and multisystem atrophy. It is also being tested in animal models of Parkinson’s disease, traumatic brain injury, stroke, intracerebral hemorrhage, epilepsy, long COVID, aging, and obesity in preparation for future human clinical trials” So many indications. Foralumab is literally huge 🔥 Phase 2a data due out the in the next three weeks. If positive, it will proven the biology mechanism and derisk the whole board of indications. That will result in a huge rerating and at the least a big pharma partnership but most likely a buyout $XBI $LABU

$TLSA when the XBI and a lot of other biotechs are getting slaughtered, Tiziana is only just starting its rerate. Hugely undervalued due to an ATM which looks like it has just closed. Now the countdown to the data release in a few weeks time which will derisk the entire platform of indications. Data unblinded next week. We could be saying hello to $3-$5 very soon! $XBI

$TLSA worth noting that RRMS accounts for the vast majority of all multiple sclerosis patients. Tiziana and KAIMRC intend to evaluate intranasal foralumab in combination with existing anti-CD20 therapies for RRMS patients who are responding poorly to standard treatment. Proving efficacy via the October data will force the market to re-rate Tiziana from a niche na-SPMS developer into a platform company actively addressing the entire global MS market. But also don’t forget the other indications- MSA, traumatic brain injury and Alzheimer’s! Just a huge opportunity here $XBI $LABU

$TLSA You know, respect to Ivor for travelling during non-peaceful times in the region and closing the deal. Clearly he cares about the company

$TLSA Now it’s just a battle of nerves. The date for the definitive data is approaching, and those who are afraid are dropping out. At this point, I’d rather face a crushing defeat than live with regret later. I believe in the drug and the previous studies; nothing is certain.

$TLSA If I buy a stock and it drops, I can hold onto it and wait, and it costs me nothing. If I am short and a stock rises while I wait, I pay interest and could lose more than my total capital.

$TLSA still very early for the stock. tlsa could rocket on good ph 2 results for na spms, and if it proves the mechanism of action then foralumab has huge, poorly served markets to target (multiple system atrophy, no treatment, ALS, no treatment, ALZ, very poor treatment options). its not far-fetched to say a good mechanism of action could lead to billions in revenue.

A small but easy-to-miss detail in today’s news: $TLSA updated the Phase 2 topline timing to October, narrowing the previous guidance of late Q3/early Q4.

$TLSA stop spamming the board with arguments. Keep it in one comment section. No one gives a crap about what yall are saying.

$TLSA MSToronto starts next week - Wednesday to Friday. I did a quick search of the contents of the conference for Foralumab - 2 posters, 2 abstracts and a reference to a presentation on the 22nd. Whether there is a late entry for presentation is not yet clear but by my reckoning only 4 trading days before the phase 2a results are due to be shared - very exciting. Only a very small patch of land to pick up pennies in the path of the steam roller for the more bearish amongst you - careful now...

$TLSA So why do the numbers look “crazy”? Because you’re no longer valuing: a single SPMS trial You’re valuing: SPMS ALS ALZ MSA Saudi partnership Peer‑reviewed mechanism Government‑validated platform Insider‑anchored buyout floor Big pharma interest Clean safety profile When you stack all of that, the model shifts from: “small biotech” → “multi‑indication neuro‑inflammation platform” And platforms are worth $5B–$10B+. So yes — once you include everything, the valuation jumps dramatically, but it’s not unrealistic. It’s simply the correct framework

$TLSA Sure, this is easy.... that drug has NOTHING TO DO WITH TIZIANA. NOTHING!!! Pay no mind to anyone claiming Black Box warnings because as far as Tiziana goes, THERE ARE NONE ON FORALUMAB!!

$TLSA CEO Elrifi was on Proactive Investors last week confirming that TLSA has four ph 2 readouts in/before q2 2027.

$TLSA ive been invested in this Company for far to long for me to feel happy. I’ve topped up at the wrong times and I’ve been really disappointed with the share price free fall. And yet, I have absolute faith in this. Probably blind, but I so want this to make a difference. Unless you’re invested, please discontinue the snide downside comments. It’s quite pathetic.

$TLSA healthy pullback, stocks don’t go straight up. tlsa still looks good technically and fundamentally

$TLSA With good data I think Foralumab could get Accelerated approval in SPMS. The company will probably discuss the data with the FDA in a month or two. The stock price would fly then...